Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Increase; Fiscal-Year Outlook Raised

MT Newswires Live10-31

Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 134 Japanese yen ($0.88) per share, up from 111 yen a year earlier.

Analysts' estimates were not readily available for comparison.

Revenue for the quarter ended Sept. 30 was 1.176 trillion yen, compared with 1.043 trillion yen a year earlier.

Analysts surveyed by Capital IQ expected 1.079 trillion yen.

The company raised its outlook for the fiscal year ending March 31, 2025, and now expects 456 yen in core EPS, from 431 yen previously.

Meanwhile, revenue for the fiscal year is now projected to be 4.480 trillion yen, compared with the prior outlook of 4.350 trillion yen. Analysts surveyed by Capital IQ expect 4.433 trillion yen.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479713907?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-31 16:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479713907","market":"nz","top_or_hot":-1,"title":"Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Increase; Fiscal-Year Outlook Raised","media":"MT Newswires Live","content":"<html><body><p> Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 134 Japanese yen ($0.88) per share, up from 111 yen a year earlier.</p><p>Analysts' estimates were not readily available for comparison.</p><p>Revenue for the quarter ended Sept. 30 was 1.176 trillion yen, compared with 1.043 trillion yen a year earlier.</p><p>Analysts surveyed by Capital IQ expected 1.079 trillion yen.</p><p>The company raised its outlook for the fiscal year ending March 31, 2025, and now expects 456 yen in core EPS, from 431 yen previously.</p><p>Meanwhile, revenue for the fiscal year is now projected to be 4.480 trillion yen, compared with the prior outlook of 4.350 trillion yen. Analysts surveyed by Capital IQ expect 4.433 trillion yen.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Increase; Fiscal-Year Outlook Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Increase; Fiscal-Year Outlook Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-31 16:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 134 Japanese yen ($0.88) per share, up from 111 yen a year earlier.Analysts' estimates were not readily available for ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TAK","symbol_name":"武田制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2479713907","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479713907","pubTimestamp":1730364982,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 134 Japanese yen ($0.88) per share, up from 111 yen a year earlier.Analysts' estimates were not readily available for compariso","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TAK":"武田制药"},"translate_title":"武田制药第二财季核心盈利、营收增长；上调财年展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":0.9},"content_text":"Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 134 Japanese yen ($0.88) per share, up from 111 yen a year earlier.Analysts' estimates were not readily available for comparison.Revenue for the quarter ended Sept. 30 was 1.176 trillion yen, compared with 1.043 trillion yen a year earlier.Analysts surveyed by Capital IQ expected 1.079 trillion yen.The company raised its outlook for the fiscal year ending March 31, 2025, and now expects 456 yen in core EPS, from 431 yen previously.Meanwhile, revenue for the fiscal year is now projected to be 4.480 trillion yen, compared with the prior outlook of 4.350 trillion yen. Analysts surveyed by Capital IQ expect 4.433 trillion yen.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479713907"}